A method for the reduction organic molecules comprising a Ruthenium-Triphosphine complex with aromatic ligands at the phosphors which are ortho or meta substituted.

A method for the reduction organic molecules comprising a Ruthenium-Triphosphine complex with aromatic ligands at the phosphors which are ortho or meta substituted.

Provided are personal care compositions comprising ester polyol esters, ester polyol esters, manufacturing methods thereof, and the use of ester polyol esters in personal care compositions.

Provided are personal care compositions comprising ester polyol esters, ester polyol esters, manufacturing methods thereof, and the use of ester polyol esters in personal care compositions.

A quaternary ammonium compound of formula (I): wherein R.sup.0, R.sup.1, R.sup.2 and R.sup.3 is each independently an optionally substituted hydrocarbyl group; X is a linking group; R.sup.4 is an optionally substituted alkylene group; n is a positive integer; W is O.sup.− or OH; b is 1 when W is OH, and b is 2 when W is O.sup.−. ##STR00001##

A quaternary ammonium compound of formula (I): wherein R.sup.0, R.sup.1, R.sup.2 and R.sup.3 is each independently an optionally substituted hydrocarbyl group; X is a linking group; R.sup.4 is an optionally substituted alkylene group; n is a positive integer; W is O.sup.− or OH; b is 1 when W is OH, and b is 2 when W is O.sup.−. ##STR00001##

This present disclosure relates to protein kinase C (PKC) modulating compounds, methods of treating a subject with cancer using the compounds, and combination treatments with a second therapeutic agent.

The present disclosure is directed to novel derivatives of terpenes, particularly ester derivatives of terpene alcohols, and methods of making them, compositions comprising them, and methods for using them.

The present disclosure is directed to novel derivatives of terpenes, particularly ester derivatives of terpene alcohols, and methods of making them, compositions comprising them, and methods for using them.

Aspects of the present disclosure include fatty acid β-hydroxyester compounds (e.g., fatty acid esters of β-hydroxybutyrate), fatty acid esters of butanediol, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions having one or more fatty acid β-hydroxyester compounds and/or one or more fatty acid esters of butanediol. Methods for treating a subject by administering one or more esters to the subject are also provided. Kits containing one or more of the subject esters are also described.